Evolus Inc Stock Investor Sentiment

EOLS Stock  USD 14.32  0.36  2.58%   
Slightly above 58% of all Evolus' private investors are looking to take a long position. The analysis of overall sentiment of trading Evolus Inc stock suggests that some investors are interested at this time. Evolus' investing sentiment can be driven by a variety of factors including economic data, Evolus' earnings reports, geopolitical events, and overall market trends.
  

Evolus Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Evolus can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
six days ago at businesswire.com         
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead Beauty Wellness Summit
businesswire News
six days ago at businesswire.com         
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead Beauty Wellness Summit
businesswire News
six days ago at finance.yahoo.com         
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead Beauty Wellness Summit
Yahoo News
six days ago at businesswire.com         
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead Beauty Wellness Summit
businesswire News
over a week ago at businesswire.com         
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
businesswire News
over a week ago at gurufocus.com         
Nantahala Capital Management, LLC Acquires Significant Stake in Senti Biosciences Inc
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Evolus Given Buy Rating at HC Wainwright
news
over a week ago at zacks.com         
Evolus Moves 5.5 percent Higher Will This Strength Last?
zacks News
over a week ago at simplywall.st         
A great week that adds to Evolus, Inc.s one-year returns, institutional investors who own 70 percent...
Simply Wall St News at Macroaxis
over a week ago at gurufocus.com         
Stonepine Capital Management, LLC Reduces Stake in Aprea Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
Yahoo News
over a week ago at businesswire.com         
Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
businesswire News
over a week ago at businesswire.com         
Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
businesswire News
over two weeks ago at zacks.com         
OrganiGram Reports Q1 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at finance.yahoo.com         
With 70 percent ownership, Evolus, Inc. boasts of strong institutional backing
Yahoo News
Far too much social signal, news, headlines, and media speculation about Evolus that are available to investors today. That information is available publicly through Evolus media outlets and privately through word of mouth or via Evolus internal channels. However, regardless of the origin, that massive amount of Evolus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evolus news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evolus relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evolus' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evolus alpha.

Evolus Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 175940 shares by David Moatazedi of Evolus at 7.28 subject to Rule 16b-3
12/10/2024
2
Acquisition by Parschauer Karah Herdman of 11789 shares of Evolus at 10.25 subject to Rule 16b-3
12/20/2024
3
Disposition of 10502 shares by David Moatazedi of Evolus at 10.8519 subject to Rule 16b-3
12/23/2024
4
Evolus Inc Trading Down 3.61 percent on Dec 27
12/27/2024
5
Evolus Inc Shares Up 6.45 percent on Jan 22
01/22/2025
6
Barclays Raises Evolus Price Target to 22.00 - MarketBeat
01/27/2025
7
Disposition of 2252 shares by Avelar Rui of Evolus at 10.8519 subject to Rule 16b-3
01/29/2025
8
Acquisition by Gill David N of 8293 shares of Evolus subject to Rule 16b-3
01/31/2025
9
Evolus Inc Stock Price Down 3.65 percent on Feb 3
02/03/2025
10
Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
02/13/2025
11
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead Beauty Wellness Summit
02/20/2025

Additional Tools for Evolus Stock Analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.